Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV4 | Q9HBA0 | 11/20 | 0.33 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16684148 | 0.95 | TRPV4 (0.33) | TRPV4ALOX5ALDH1A1LMNAGAA | |
| SCHEMBL3483982 | 0.95 | TRPV4 (0.33) | TRPV4ALOX5ALDH1A1LMNAGAA | |
| SCHEMBL13021466 | 0.92 | TRPV4 (0.33) | TRPV4ALDH1A1LMNAGAASMN1; SMN2 | |
| SCHEMBL14943027 | 0.90 | ALDH1A1 (0.32) | TRPV4ALDH1A1LMNAGAASMN1; SMN2 | |
| SCHEMBL14943026 | 0.90 | ALDH1A1 (0.32) | TRPV4ALDH1A1LMNAGAASMN1; SMN2 | |
| SCHEMBL4559091 | 0.89 | ALOX5 (0.31) | ALOX5CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL16684145 | 0.87 | AR (0.33) | TRPV4ALDH1A1LMNAGAASMN1; SMN2 | |
| SCHEMBL13022858 | 0.84 | AR (0.35) | ALDH1A1LMNAGAASMN1; SMN2CYP1A2 | |
| SCHEMBL12979688 | 0.83 | TRPV4 (0.34) | TRPV4ALDH1A1LMNAGAASMN1; SMN2 | |
| SCHEMBL14931376 | 0.83 | ALOX5 (0.32) | ALOX5CYP1A2CYP3A4CYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100279983-A1 | NOVEL INHIBITORS OF BETA-LACTAMASE | METHYLGENE INC. | 2010-11-04 | — | — | US | claimed |
| US-20100279983-A1 | NOVEL INHIBITORS OF BETA-LACTAMASE | METHYLGENE INC. | 2010-11-04 | — | — | US | disclosed |
| EP-2049200-A2 | NOVEL INHIBITORS OF BETA-LACTAMASE | MethylGene Inc. (CA) | 2009-04-22 | — | — | EP | disclosed |
| WO-2008073142-A2 | NOVEL INHIBITORS OF BETA-LACTAMASE | MERCK & CO., INC. (US) | 2008-06-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100279983-A1 | NOVEL INHIBITORS OF BETA-LACTAMASE | MGAM, MGAM2, PGLS | TRPV4 4788/4885ALOX5 2269/4885ALDH1A1 2190/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.